Zobrazeno 1 - 10
of 256
pro vyhledávání: '"T L Innerarity"'
Autor:
E H Ludwig, P N Hopkins, A Allen, L L Wu, R R Williams, J L Anderson, R H Ward, J M Lalouel, T L Innerarity
Publikováno v:
Journal of Lipid Research, Vol 38, Iss 7, Pp 1361-1373 (1997)
To search for unique mutations in the apolipoprotein B (apoB) gene that disrupt the binding of LDL to its receptor and cause hypercholesterolemia, we examined more than 800 patients with high LDL cholesterol levels and/or coronary artery disease (CAD
Externí odkaz:
https://doaj.org/article/67689e897eaf42f4a73acc830168b206
Publikováno v:
Journal of Lipid Research, Vol 35, Iss 8, Pp 1469-1476 (1994)
Familial defective apolipoprotein B-100 (FDB) is a genetic disorder apparently caused by a single amino acid substitution (Arg3500–>Gln) that disrupts the binding of low density lipoproteins (LDL) to the LDL receptor. The plasma of FDB heterozygote
Externí odkaz:
https://doaj.org/article/b80692fa64d2496c8a5b1a82a01aefe9
Publikováno v:
Journal of Lipid Research, Vol 23, Iss 5, Pp 702-714 (1982)
Cholesteryl ester-rich beta-very low density lipoproteins (beta-VLDL) are beta-migrating lipoproteins that accumulate in the d < 1.006 g/ml fraction of plasma from cholesterol-fed animals and from patients with Type III hyperlipoproteinemia. They can
Externí odkaz:
https://doaj.org/article/1a2a421d095b4c5ca2f680589109e653
Publikováno v:
Journal of Lipid Research, Vol 21, Iss 8, Pp 970-980 (1980)
Animals fed cholesterol accumulate several types of cholesterol-rich lipoproteins in their plasma and ultimately develop cholesteryl ester deposition in tissue macrophages. Previous studies in the cholesterol-fed dog have shown that one class of chol
Externí odkaz:
https://doaj.org/article/bf4c9179cdf44d02acad4d4ce982f548
Publikováno v:
Journal of Lipid Research, Vol 25, Iss 12, Pp 1277-1294 (1984)
Plasma lipoprotein metabolism is regulated and controlled by the specific apolipoprotein (apo-) constituents of the various lipoprotein classes. The major apolipoproteins include apoE, apoB, apoA-I, apoA-II, apoA-IV, apoC-I, apoC-II, and apoC-III. Sp
Externí odkaz:
https://doaj.org/article/6315e32536c04f099b26da86afa923fb
Publikováno v:
Journal of Lipid Research, Vol 30, Iss 4, Pp 587-596 (1989)
Monoclonal antibody (Mab) 1D7 is specific for human apolipoprotein (apo) E and blocks binding of lipid-associated apoE to the low density lipoprotein (LDL) receptor. We report here that 1D7 can also block the binding of apoE-free LDL to the LDL recep
Externí odkaz:
https://doaj.org/article/74d967de0bc2468c991f13a4c987354d
Publikováno v:
Journal of Lipid Research, Vol 28, Iss 12, Pp 1410-1423 (1987)
Apolipoprotein (apo) B-100, the protein constituent of low density lipoproteins (LDL), is the determinant responsible for LDL binding to the apoB,E(LDL) receptor on cells. The current study was designed to identify the region(s) of apoB-100 that inte
Externí odkaz:
https://doaj.org/article/87c96d93b6d6489493836c1589be0789
Publikováno v:
Journal of Lipid Research, Vol 28, Iss 12, Pp 1482-1494 (1987)
The rat hepatoma cell line Fu5AH has the unusual property of accumulating massive amounts of cholesteryl ester upon incubation with hypercholesterolemic serum, and especially when incubated with beta-very low density lipoproteins (beta-VLDL) from cho
Externí odkaz:
https://doaj.org/article/9c1888809180419c9fbf0476ccc277a5
Publikováno v:
Journal of Clinical Investigation. 101:2658-2664
The subendothelial retention of LDLs through their interaction with proteoglycans has been proposed to be a key process in the pathogenesis of atherosclerosis. In vitro studies have identified eight clusters of basic amino acids in delipidated apo-B1
Autor:
R. H. Ward, J L Anderson, E. H. Ludwig, Roger R. Williams, A Allen, T L Innerarity, Lily L. Wu, Paul N. Hopkins, Jean-Marc Lalouel
Publikováno v:
Journal of Lipid Research, Vol 38, Iss 7, Pp 1361-1373 (1997)
To search for unique mutations in the apolipoprotein B (apoB) gene that disrupt the binding of LDL to its receptor and cause hypercholesterolemia, we examined more than 800 patients with high LDL cholesterol levels and/or coronary artery disease (CAD